SC
JBIO

Steven Cohen’s Jade Biosciences JBIO Stock Holding History

Steven Cohen’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,200
Closed -$157K – 4003
2026
Q1 		$157K Buy
+11,200
New +$162K ﹤0.01% 3564

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Steven Cohen's JBIO Position: Q2 2026 in Review

Steven Cohen reduced its Jade Biosciences (JBIO) stake by 37% in Q2 2026, selling an estimated $2.03M and leaving 167,204 shares worth $3.72M. The position accounts for ﹤0.01% of the portfolio, ranked #1981.

Steven Cohen first reported a position in JBIO in Q3 2021 and has held it in 8 quarters since. The position peaked at $11.8M in Q1 2024. 153 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Steven Cohen held 167,204 shares of Jade Biosciences worth $3.72M as of Q2 2026.
  • Steven Cohen sold 97,111 Jade Biosciences shares in Q2 2026, an estimated $2.03M.
  • Jade Biosciences made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #1981 holding.
  • Steven Cohen first reported a position in Jade Biosciences in Q3 2021 and has held it in 8 quarters since.
  • Steven Cohen's Jade Biosciences position peaked at $11.8M in Q1 2024.
  • 153 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.